bivacor.com Open in urlscan Pro
159.203.44.142  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content
Toggle Navigation
 * Home
 * Heart Failure
 * Device
 * Technology
 * About Us
 * Careers
 * Contact
 * More Information
   * News
   * Media Coverage
   * Publications
   * Acknowledgements


Toggle Navigation
 * Home
 * Heart Failure
 * Device
 * Technology
 * About Us
 * Careers
 * Contact
 * More Information
   * News
   * Media Coverage
   * Publications
   * Acknowledgements



HomeMichael2024-06-17T12:18:26-07:00

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company’s Total
Artificial Heart.


REPLACING HEARTS.


RESTORING LIVES.


HEART FAILURE



Heart Failure (HF) is a devastating disease that affects more than 11 million
people in the US and Europe, with an incidence of 1.1 million new cases per
year. Furthermore, current growth rates predict a 25% increase in the incidence
of HF by 2030.

According to the US National Institutes of Health (NIH), 100,000 patients could
immediately benefit from mechanical circulatory support (MCS), and the European
market is similarly sized. Without intervention, patients with severe HF have a
bleak outlook. For these patients, drug therapy is a limited, relatively
ineffective option. Although a heart transplant would meet their needs, only
4000 donor hearts are available globally each year.


TOTAL ARTIFICIAL HEART THERAPY

Implantation of a TAH is a treatment option for patients with end-stage HF who
need support while on a heart transplant waiting list or who do not qualify for
a transplant. Removal of the native ventricles allows the device to completely
replace the function of the native heart.




DEVICE



The BiVACOR Total Artificial Heart (TAH) is designed to take over the complete
function of a patient’s failing heart.



POWERFUL

The centrifugal pumps can provide high flows over 12 L/min for dynamic activity.

SMART

Smart controllers adapt the pump operation to changes in the patient’s activity.

DURABLE

An anticipated device life of up to 10 years or more.

SMALL

Small enough for a child, powerful enough for an adult.

PORTABLE

A small external controller and batteries to give patients freedom.





TECHNOLOGY



A SINGLE MOVING PART

Two centrifugal impellers placed on a single rotor provide perfusion to the left
and right sides of the body.

ADVANTAGES OF A ROTARY PUMP

Specially designed pump blades allow high flows and low power consumption.

PHYSIOLOGIC INTERACTION

The device’s patented left-right flow-balancing system allows dynamic adaptation
to change in the patient’s physiology.

ACTIVE MAGNETIC LEVITATION

Magnetic levitation provides precise, stable operation with no mechanical wear.

BLOOD COMPATIBILITY

Special large gaps within the pump reduce blood cell damage and the risk of
clotting.


BIVACOR TAH ANIMATION



The BiVACOR TAH is designed to be a long-term device that can replace the total
function of the patient’s native heart. The small, compact device uses proven
rotary blood pump technology to provide the required cardiac output.

The BiVACOR system comprises a magnetically levitated rotor located between
opposing pump casings. The key feature that enables this device to support both
the left and right sides of the heart is the left and right impeller blades,
which are mounted on either side of the rotating hub. The hub is levitated and
rotated via an electromagnetic motor and bearing arrangement on top of the pump
casings. The dedicated hydraulic design of the impellers, combined with
state-of-the-art magnetic levitation (MAGLEV) technology, permits control of the
circulation to be fine-tuned by means of a differential fluid output.

An external controller and batteries provide power to the internal device via a
percutaneous driveline.

BiVACOR Artificial Heart by Amerra on Sketchfab

BiVACOR Artificial Heart by Amerra on Sketchfab




ABOUT US




BiVACOR® is a privately held company founded in 2008. Our staff includes
world-class engineers, medical specialists, and business executives, who are
diligently working to advance this ground-breaking technology. Together, we have
established a strong collaborative network that extends both nationally and
internationally. Our world headquarters is in Huntington Beach, California, with
our international office in Brisbane, Australia.


MEET THE TEAM



We are all around the world!




JIM DILLON

Chief Executive Officer

Jim Dillon is an experienced medical device executive whose career focus in
heart failure has included developing cardiovascular therapies to enable native
heart recovery, reducing the size of a patient’s myocardial infarction,
repairing adult and congenital cardiac defects, and volume management for
acutely decompensated congestive heart failure patients.

Over his multi-decade career, Mr. Dillon has held a series of corporate
strategic and sales leadership positions as a key contributor to multiple
successful medical device companies. Prior to his recent role as CEO of
clinical-stage private company BioVentrix, he founded and secured financing for
Reprieve Cardiovascular, he held senior executive sales and marketing positions
with Abiomed and St. Jude Medical.





DANIEL TIMMS, PHD

Chief Technical Officer

Daniel Timms, PhD, is the founder of BiVACOR, Inc. A graduate of the Queensland
University of Technology, Dr. Timms completed his postdoctoral training at The
Prince Charles Hospital’s cardiac transplant center in Brisbane, Australia, and
at the Helmholtz Institute in Aachen, Germany, one of Europe’s leading
cardiovascular device research centers.

He has more than 15 years of experience in mechanical circulatory support
development.





WILLIAM COHN, MD

Chief Medical Officer

William E. Cohn, MD, is Director of the Center for Technology and Innovation;
Associate Director of Laboratory Surgery Research in the Center for Cardiac
Support; and Co-Director of the Cardiovascular Surgical Research Laboratory at
the Texas Heart Institute, in Houston, Texas, USA.

He is a professor of surgery at Baylor College of Medicine in the Division of
Transplant and Assist Devices and an adjunct professor of bioengineering at both
Rice University and the University of Houston.

His major research interests are focused on the development of medical
technology and integration of new technology into clinical practice.




CAREERS



BiVACOR is always accepting applications for motivated engineers and scientists.

Please send us your application documents via the career page or at
HR@BiVACOR.com




CORPORATE OFFICE

BiVACOR, Inc.
5432 Bolsa Avenue, Suite A & B,
Huntington Beach, CA 92649, USA
Email: admin@bivacor.com


CLINICAL OFFICE

BiVACOR, Inc.
2450 Holcombe Avenue
Houston, TX 77021, USA
Email: admin@bivacor.com


AUSTRALIAN OFFICE

BiVACOR, Pty. Ltd.
16 Nexus Way
Southport, QLD 4215, Australia
Email: admin@bivacor.com

The BiVACOR trademarks are federally registered trademarks owned by BiVACOR.
Any unauthorized use is expressly prohibited.

Investigational Device. Limited to Investigational Use Only in The United
States.

© 2024 BiVACOR Inc. | Website Built & Hosted by eLearnza

Page load link

Go to Top